Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2007

01-03-2007 | Epidemiology

A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland

Authors: Cezary Cybulski, Dominika Wokołorczyk, Tomasz Huzarski, Tomasz Byrski, Jacek Gronwald, Bohdan Górski, Tadeusz Dębniak, Bartłomiej Masojć, Anna Jakubowska, Thierry van de Wetering, Steven A. Narod, Jan Lubiński

Published in: Breast Cancer Research and Treatment | Issue 1/2007

Login to get access
Metadata
Title
A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland
Authors
Cezary Cybulski
Dominika Wokołorczyk
Tomasz Huzarski
Tomasz Byrski
Jacek Gronwald
Bohdan Górski
Tadeusz Dębniak
Bartłomiej Masojć
Anna Jakubowska
Thierry van de Wetering
Steven A. Narod
Jan Lubiński
Publication date
01-03-2007
Published in
Breast Cancer Research and Treatment / Issue 1/2007
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-006-9320-y

Other articles of this Issue 1/2007

Breast Cancer Research and Treatment 1/2007 Go to the issue

Clinical Trial

The decision-making experience among women diagnosed with stage I and II breast cancer

Letter to the Editor

Do nipple aspirate fluid epithelial cells and their morphology predict breast cancer development?

Epidemiology

Body size, weight change, fat distribution and breast cancer risk in Hispanic and non-Hispanic white women

LETTER TO THE EDITOR

Detection of polymorphisms in the promoters of matrix metalloproteinases 2 and 9 genes in breast cancer in South Brazil: preliminary results

Epidemiology

Variants in estrogen metabolism and biosynthesis genes and urinary estrogen metabolites in women with a family history of breast cancer

Preclinical study

Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivo
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits